Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated.

International Myeloma Foundation: “Multiple Myeloma and Anemia,” “Heart and Lung Complications.” Memorial Sloan Kettering Cancer Center: “Bone-Related Problems in Multiple Myeloma ...

Despite significant advancements in multiple myeloma treatment, new solutions are desperately needed to improve long-term outcomes, particularly for newly diagnosed and transplant-ineligible patients.

Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...

You will be able to get a quick price and instant permission to reuse the content in many different ways. The humerus is a common site for metastatic bone disease and the common primaries include ...

Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial ...

Multiple myeloma is part of the spectrum of diseases ranging from MGUS to plasma cell leukemia, and similar to MGUS, is characterized by proliferation of a plasma cell clone and subsequent ...

The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J’s Carvykti, although Wall Street analysts were divided on how the two drugs compare. Carvykti ...

Brain magnetic resonance imaging (MRI) showed multiple contrast enhancing subdural lesions (fig 1). Based on the MRI finding, differential diagnoses included empyema, tuberculosis, neurocysticercosis, ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead Sciences' Kite Pharma to treat relapsed or refractory multiple myeloma (RRMM). After seeing the data ...